Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

被引：38

作者：

Tuccori, Marco ^{[1
]}

Focosi, Daniele ^{[2
]}

Blandizzi, Corrado ^{[1
,5
]}

Pelosini, Matteo ^{[2
]}

Montagnani, Sabrina ^{[1
,5
]}

Maggi, Fabrizio ^{[3
,4
]}

Pistello, Mauro ^{[3
,4
]}

Antonioli, Luca ^{[1
]}

Fornai, Matteo ^{[1
]}

Pepe, Pasquale ^{[6
]}

Rossi, Giuseppe ^{[6
]}

Petrini, Mario ^{[2
]}

机构：

[1] Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, Pisa, Italy

[2] Univ Pisa, Div Haematol, Dept Oncol Transplantat & New Technol Med, Pisa, Italy

[3] Univ Pisa, Virol Sect, Pisa, Italy

[4] Univ Pisa, Retrovirus Ctr, Dept Expt Pathol, Pisa, Italy

[5] Tuscan Reg Ctr Pharmacovigilance, Pisa, Italy

[6] CNR, Unit Epidemiol & Biostat, Inst Clin Physiol, Pisa, Italy

来源：

ONCOLOGIST | 2010年 / 15卷 / 11期

关键词：

Rituximab; Progressive multifocal leukoencephalopathy; JCV; Monoclonal antibody; Non-Hodgkin's lymphoma; ADVERSE DRUG EVENTS; NATALIZUMAB; EFALIZUMAB; THERAPY; PROJECT; DISEASE; PML;

D O I：

10.1634/theoncologist.2010-0098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives. Rituximab is an anti-CD20 monoclonal antibody that promotes better treatment outcomes in patients with non-Hodgkin's lymphoma (NHL). Case series of progressive multifocal leukoencephalopathy (PML) in patients receiving rituximab within polychemotherapy regimens have led to the introduction of a black box warning, but no risk estimation has ever been provided. Methods. We performed a retrospective, monocentric cohort study on 976 NHL patients diagnosed in 1994-2008, including 517 patients who received at least one dose of rituximab. Results. Inclusion of rituximab into standard chemotherapy regimens for NHL caused a significantly higher incidence of PML cases (rate difference, 2.2 every 1,000 patient-years; 95% confidence interval, 0.1-4.3). Interpretation. Based on this finding, clinical surveillance of PML-related symptoms is recommended in NHL patients exposed to rituximab. The Oncologist 2010;15:1214-1219

引用

页码：1214 / 1219

页数：6

共 50 条

[41] Results in the treatment of Hodgkin's disease and non-Hodgkin malignant lymphomas
不详
BULLETIN DU CANCER, 2003, 90 : S88 - S95
[42] Hodgkin's disease and non-Hodgkin lymphomas
Gutiérrez, EO
REVISTA CLINICA ESPANOLA, 1999, 199 : 44 - 51
[43] BCG AND TREATMENT OF NON-HODGKIN LYMPHOMAS
HOERNI, B
INTERNATIONAL JOURNAL OF IMMUNOTHERAPY, 1986, 2 (01): : 1 - 3
[44] Obinutuzumab for the treatment of non-Hodgkin lymphomas
Hernandez, Juana
Nielsen, Tina
Klein, Christian
Wenger, Michael
NATURE, 2018, 563 (7731)
[45] Progressive Multifocal Leukoencephalopathy Following Rituximab Treatment in a Patient With Rheumatoid Arthritis
Fleischmann, R. M.
ARTHRITIS AND RHEUMATISM, 2009, 60 (11): : 3225 - 3228
[46] Classification of non-Hodgkin's lymphomas
Norton, AJ
BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (04): : 641 - 652
[47] Progress in the non-Hodgkin's lymphomas
Yuen, AR
ANNALS OF ONCOLOGY, 1999, 10 : 19 - 22
[48] Radioimmunotherapy of non-Hodgkin's lymphomas
Cheson, Bruce D.
CURRENT DRUG TARGETS, 2006, 7 (10) : 1293 - 1300
[49] Non-Hodgkin's lymphomas - Preface
Linch, DC
BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (04): : R9 - R9
[50] Non-Hodgkin's lymphomas in breast
Gursan, N.
Ozmen, S.
Sener, E.
VIRCHOWS ARCHIV, 2015, 467 : S61 - S61

← 1 2 3 4 5 →